Skip to main content

Table 4 Changes from Baseline of n-6 and n-3 PUFAs in Erythrocytes, Platelets and Serum Phospholipids upon 8 weeks of HPN

From: Efficacy of a long-term home parenteral nutrition regimen containing fish oil-derived n-3 polyunsaturated fatty acids: a single-centre, randomized, double blind study

  Test group (MCT/LCT/FO-derived n-3 PUFAs) N = 11* Control group (MCT/LCT) N = 9*
n-6 PUFAs
 Linoleic Acid (LA)
  Erythrocytes (%)
   Baseline 10.1 ± 1.0 10.2 ± 1.5
   V2 (8 weeks HPN) 9.3 ± 0.9 10.6 ± 1.4
Mean treatment difference (V2-BL) = − 1.14%, CI 95 [− 2.0; − 0.3], p = 0.0107, t-test
  Platelets (%)
   Baseline 22.1 ± 3.1 16.9 ± 4.0
   V2 (8 weeks HPN) 21.8 ± 2.9 20.9 ± 4.4
Mean treatment difference (V2-BL) = − 5.0%, CI 95 [− 7.3; − 2.7], p = 0.0002, t-test
  Serum Phospholipids (%)
   Baseline 20.0 ± 2.3 20.0 ± 3.1
   V2 (8 weeks HPN) 18.1 ± 1.8 20.9 ± 2.6
Mean treatment difference (V2-BL) = − 3.3%, CI 95 [− 4.6; − 2.1, p < 0.0001, t-test
 Arachidonic Acid (AA)
  Erythrocytes (%)
   Baseline 16.8 ± 2.0 16.8 ± 1.3
   V2 (8 weeks HPN) 13.2 ± 1.9 17.0 ± 2.4
Mean treatment difference (V2-BL) = − 3.8%, CI 95 [− 5.9; − 1.8], p = 0.0011, t-test
  Platelets (%)
   Baseline 10.9 ± 3.8 12.9 ± 4.0
   V2 (8 weeks HPN) 8.4 ± 1.6 11.3 ± 4.2
Mean treatment difference (V2-BL) = − 1.3%, CI 95 [− 3.8; 1.2], p = 0.2883, t-test
  Serum Phospholipids (%)
   Baseline 10.6 ± 1.5 9.7 ± 2.2
   V2 (8 weeks HPN) 8.2 ± 1.4 9.6 ± 1.9
Mean treatment difference (V2-BL) = − 2.7%, CI 95 [− 4.0; − 1.4], p = 0.0005, t-test
 Dihomo-γ-linolenic acid (DGLA)
  Erythrocytes (%)
   Baseline 2.2 ± 0.4 2.4 ± 0.5
   V2 (8 weeks HPN) 1.7 ± 0.3 2.4 ± 0.5
Mean treatment difference (V2-BL) = − 0.4%, CI 95 [− 0.6; − 0.1], p = 0.0044, t-test
  Platelets (%)
   Baseline 1.7 ± 0.4 1.9 ± 0.4
   V2 (8 weeks HPN) 1.1 ± 0.4 1.8 ± 0.4
Mean treatment difference (V2-BL) = − 0.4%, CI 95 [− 0.8; − 0.01], p = 0.0471, t-test
  Serum Phospholipids (%)
   Baseline 3.1 ± 1.0 4.2 ± 1.2
   V2 (8 weeks HPN) 2.1 ± 0.9 3.8 ± 1.3
Mean treatment difference (V2-BL) = − 0.5%, CI 95 [− 1.2; 0.1], p = 0.1156, t-test
 γ-Linolenic acid (GLA)
  Erythrocytes (%)
   Baseline 0.08 ± 0.03 0.09 ± 0.4
   V2 (8 weeks HPN) 0.05 ± 0.02 0.10 ± 0.05
Mean treatment difference (V2-BL) = − 0.05%, CI 95 [− 0.09; − 0.01], p = 0.0118, t-test
  Platelets (%)
   Baseline 0.5 ± 0.3 0.4 ± 0.1
   V2 (8 weeks HPN) 0.3 ± 0.1 0.5 ± 0.2
Mean treatment difference (V2-BL) = − 0.3%, CI 95 [− 0.5; − 0.1], p = 0.0049, t-test
  Serum Phospholipids (%)
   Baseline 0.14 ± 0.08 0.16 ± 0.07
   V2 (8 weeks HPN) 0.07 ± 0.04 0.13 ± 0.04
Mean treatment difference (V2-BL) = − 0.03%, CI 95 [− 0.09; 0.04], p = 0.3647, t-test
n-3 PUFAs
 Eicosapentaenoic acid (EPA)
  Erythrocytes (%)
   Baseline 0.7 ± 0.2 0.7 ± 0.2
   V2 (8 weeks HPN) 2.8 ± 0.9 0.7 ± 0.1
Mean treatment difference (V2-BL) = 2.1%, CI 95 [1.4; 2.8], p < 0.0001, t-test
  Platelets (%)
   Baseline 0.7 ± 0.2 0.6 ± 0.2
   V2 (8 weeks HPN) 4.3 ± 2.0 0.6 ± 0.2
Mean treatment difference (V2-BL) = 3.4%, CI 95 [2.1; 4.8], p < 0.0001, t-test
  Serum Phospholipids (%)
   Baseline 1.1 ± 0.3 1.1 ± 0.4
   V2 (8 weeks HPN) 4.6 ± 1.5 1.0 ± 0.3
Mean treatment difference (V2-BL) = 3.5%, CI 95 [2.5; 4.5], p < 0.0001, t-test
 Docosahexaenoic acid (DHA)
  Erythrocytes (%)
   Baseline 4.5 ± 1.3 4.1 ± 1.1
   V2 (8 weeks HPN) 6.5 ± 1.1 4.0 ± 0.5
Mean treatment difference (V2-BL) = 2.2%, CI 95 [1.0; 3.3], p = 0.0008, t-test
  Platelets (%)
   Baseline 1.8 ± 0.4 1.4 ± 0.5
   V2 (8 weeks HPN) 3.6 ± 0.7 1.5 ± 0.4
Mean treatment difference (V2-BL) = 1.8%, CI 95 [1.3; 2.3], p < 0.0001, t-test
  Serum Phospholipids (%)
   Baseline 3.1 ± 0.7 2.7 ± 1.0
   V2 (8 weeks HPN) 5.8 ± 1.6 2.7 ± 0.6
Mean treatment difference (V2-BL) = 2.6%, CI 95 [1.6; 3.6], p < 0.0001, t-test
 Docosapentaenoic acid (DPA)
  Erythrocytes (%)
   Baseline 2.9 ± 0.5 2.9 ± 0.5
   V2 (8 weeks HPN) 4.0 ± 0.5 3.0 ± 0.7
Mean treatment difference (V2-BL) = 0.8%, CI 95 [0.3; 1.4], p = 0.0058, t-test
  Platelets (%)
   Baseline 0.9 ± 0.2 1.1 ± 0.3
   V2 (8 weeks HPN) 1.4 ± 0.2 1.0 ± 0.4
Mean treatment difference (V2-BL) = 0.5%, CI 95 [0.3; 0.7], p = 0.0003, t-test
  Serum Phospholipids (%)
   Baseline 1.0 ± 0.2 1.0 ± 0.3
   V2 (8 weeks HPN) 1.6 ± 0.4 1.0 ± 0.3
Mean treatment difference (V2-BL) = 0.4%, CI 95 [0.2; 0.6], p = 0.0009, t-test
  1. * Number of baseline values (test group): N = 14; Number of baseline values (control group): N = 13